Timing of Cancer Treatments Linked to Improved Survival Rates in New Study

A recent study has revealed that the timing of immunotherapy treatments for lung cancer patients significantly impacts their survival rates. Patients receiving treatment before 3 p.m. experienced an average of nearly a year longer life and better progression-free survival compared to those treated later in the day. The study, involving 210 patients, highlighted that early treatment led to nearly double the time without cancer progression. Researchers emphasize the need for further studies to confirm these findings, as the implications could revolutionize cancer treatment protocols. This research underscores the importance of circadian rhythms in immune response and treatment efficacy.

Key Details: • Patients treated before 3 p.m. had an average survival of nearly one year longer. • The study involved 210 patients diagnosed with non-small-cell lung cancer. • Early treatment resulted in an average of 11.3 months without cancer progression versus 5.7 months for later treatment. • About 45% of early treatment patients were still alive at the end of the study, compared to 15% of those treated later.